Uraemic toxins for consideration by the cardiologist-Beyond traditional and non-traditional cardiovascular risk factors

Atherosclerosis

Volumn 211, Issue 2, 2010, Pages 381-383

  Massy, Ziad A ^a,b,c   Barreto, Daniela V ^a,b   Barreto, Fellype C ^a,b   Vanholder, Raymond ^d  

^a INSERM   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 CRESYLSULPHATE; AMINO ACID DERIVATIVE; CREATININE; PARA CRESOL; PHENOL; PHENYLALANINE; SULFATE; TYROSINE; UNCLASSIFIED DRUG; UREMIC TOXIN;

ANGIOCARDIOGRAPHY; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CHRONIC KIDNEY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; HUMAN; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; TRADITIONAL MEDICINE;

CARDIOLOGY; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; EUROPE; HUMANS; INFLAMMATION; KIDNEY; RENAL DIALYSIS; RISK FACTORS; UREMIA;

EID: 77955266740     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.04.010     Document Type: Note

References (15)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl. 1):S1-266.
2. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351(13):1296-1305.
3. Vanholder R., Massy Z., Argiles A., Spasovski G., Verbeke F., Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005, 20(6):1048-1056.
4. Stenvinkel P., Carrero J.J., Axelsson J., Lindholm B., Heimburger O., Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008, 3(2):505-521.
5. Vanholder R., De Smet R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003, 63(5):1934-1943.
6. Liabeuf S., Barreto D.V., Barreto F.C., et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010, 25(4):1183-1191.
7. Meijers B.K., Bammens B., De Moor B., et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008, 73(10):1174-1180.
8. Meijers B.K., Van Kerckhoven S., Verbeke K., et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009, 54(5):891-901.
9. Schepers E., Meert N., Glorieux G., et al. P-cresylsulphate the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007, 22(2):592-596.
10. Barreto F.C., Barreto D.V., Liabeuf S., et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009, 4(10):1551-1558.
11. De Preter V., Vanhoutte T., Huys G., et al. Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol 2007, 292(1):G358-368.
12. Birkett A., Muir J., Phillips J., Jones G., O'Dea K. Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr 1996, 63(5):766-772.
13. Meijers B.K., De Preter V., Verbeke K., Vanrenterghem Y., Evenepoel P. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2010, 25(1):219-224.
14. Niwa T., Ise M., Miyazaki T., Meada K. Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 1993, 65(1):82-87.
15. Schulman G., Agarwal R., Acharya M., et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006, 47(4):565-577.